HK1211602A1 - Cell penetrating peptides which bind irf5 irf5 - Google Patents

Cell penetrating peptides which bind irf5 irf5

Info

Publication number
HK1211602A1
HK1211602A1 HK15112385.1A HK15112385A HK1211602A1 HK 1211602 A1 HK1211602 A1 HK 1211602A1 HK 15112385 A HK15112385 A HK 15112385A HK 1211602 A1 HK1211602 A1 HK 1211602A1
Authority
HK
Hong Kong
Prior art keywords
irf5
bind
cell penetrating
penetrating peptides
peptides
Prior art date
Application number
HK15112385.1A
Other languages
English (en)
Chinese (zh)
Inventor
Julie Demartino
Nader Fotouhi
Ann Hoffman
Kuo Sen Huang
Francesca Milletti
Sandip Panicker
Dinesh Srinivasan
Seng-Lai Tan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1211602A1 publication Critical patent/HK1211602A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
HK15112385.1A 2012-10-08 2015-12-16 Cell penetrating peptides which bind irf5 irf5 HK1211602A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261710817P 2012-10-08 2012-10-08
PCT/EP2013/070759 WO2014056813A1 (fr) 2012-10-08 2013-10-07 Peptides pénétrant dans les cellules qui se lient à irf5

Publications (1)

Publication Number Publication Date
HK1211602A1 true HK1211602A1 (en) 2016-05-27

Family

ID=49322357

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112385.1A HK1211602A1 (en) 2012-10-08 2015-12-16 Cell penetrating peptides which bind irf5 irf5

Country Status (10)

Country Link
US (1) US20160009772A1 (fr)
EP (1) EP2904003A1 (fr)
JP (1) JP2015534568A (fr)
KR (1) KR20150064066A (fr)
CN (1) CN104736556A (fr)
CA (1) CA2884220A1 (fr)
HK (1) HK1211602A1 (fr)
MX (1) MX2015004145A (fr)
RU (1) RU2015113348A (fr)
WO (1) WO2014056813A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
EP3270951B1 (fr) 2015-03-16 2020-09-09 California Institute of Technology Agents de capture spécifiques de la neurotoxine botulique, compositions et méthodes d'utilisation et de préparation associées
WO2017044855A2 (fr) 2015-09-09 2017-03-16 Rutgers, The State University Of New Jersey Peptides de pénétration cellulaire qui inhibent la localisation nucléaire d'irf5
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3519425B1 (fr) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions pour la détection, l'inhibition et l'imagerie de l'indoléamine 2,3-dioxygénase 1 (ido1) et leurs méthodes de production et d'utilisation
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
US10420792B2 (en) 2017-02-24 2019-09-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Method of treating severe asthma
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
EP3638687A1 (fr) 2017-06-15 2020-04-22 Indi Molecular, Inc. Agents de capture spécifiques d'il-17f et il-17a, compositions et procédés d'utilisation et de production
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (fr) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Régulation de protéine accordable par er
US20220120756A1 (en) * 2019-02-05 2022-04-21 Purdue Research Foundation Method and composition matter for immunoproteasome-mediated delivery into living cells
US20220220168A1 (en) * 2019-05-08 2022-07-14 The Feinstein Institues For Medical Research Interferon regulatory factor 5 inhibitors and uses thereof
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2022098743A1 (fr) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imagerie et procédés thérapeutiques ciblant le récepteur 1 de folate (folr1)
CN114015696B (zh) * 2021-11-09 2023-06-16 海南大学 卵形鲳鲹干扰素调节因子irf6基因、蛋白、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184882T1 (de) * 1992-12-11 1999-10-15 Univ Florida Materialien und methoden zur schädlingsbekämpfung
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0906339A2 (fr) * 1996-03-27 1999-04-07 NG, Gordon, Y., K. Antagonistes recepteurs et transporteurs
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2002079784A1 (fr) * 2001-03-30 2002-10-10 Suntory Limited Modele structurel de recepteur couple a la proteine g et procede de conception de ligand se liant au recepteur couple a la proteine g au moyen du modele structurel
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
US20140030218A1 (en) * 2011-01-05 2014-01-30 Imperial Innovations Limited Treatment And Screening

Also Published As

Publication number Publication date
CN104736556A (zh) 2015-06-24
MX2015004145A (es) 2015-07-06
RU2015113348A (ru) 2016-11-27
US20160009772A1 (en) 2016-01-14
JP2015534568A (ja) 2015-12-03
EP2904003A1 (fr) 2015-08-12
WO2014056813A1 (fr) 2014-04-17
KR20150064066A (ko) 2015-06-10
CA2884220A1 (fr) 2014-04-17

Similar Documents

Publication Publication Date Title
HK1211602A1 (en) Cell penetrating peptides which bind irf5 irf5
EP2919313A4 (fr) Electrolyte solide
EP2811554A4 (fr) MATÉRIAU D'ANODE FAIT EN UN ALLIAGE À BASE DE Si
HUE049541T2 (hu) Kis cella aktiválási eljárása
EP2857033A4 (fr) Peptide à perméation cutanée
EP2876715A4 (fr) Pile à combustible
EP2911230A4 (fr) Cellule
SG10201700670WA (en) Cell culture
EP2831949A4 (fr) Cellules à sodium-oxygène
EP2812347A4 (fr) Peptide induisant une autophagie
EP2899786A4 (fr) Pile à combustible
EP2919308A4 (fr) Pile à combustible du type à polyélectrolyte
HK1209138A1 (en) Peptides
EP2835852A4 (fr) Pile à combustible
EP2830130A4 (fr) Pile à combustible
EP2863459A4 (fr) Cellule plate
EP2882020A4 (fr) Pile à combustible
GB201721211D0 (en) Improved materials
GB201200555D0 (en) Peptide
GB201212550D0 (en) B cell assay
GB201204868D0 (en) Peptides
GB2500031B (en) Fuel cells
EP2863460A4 (fr) Pile à combustible
GB201211873D0 (en) Cell culture
PT2891663T (pt) Péptidos derivados de psf1